Global Immunohistochemistry (IHC) Market Analysis 2021-2026


Dublin, November 22, 2021 (GLOBE NEWSWIRE) – The “Global Immunohistochemistry (IHC) Market By Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnosis (Cancer, Infectious Diseases, Autoimmune), Research, Forensic Medicine), End User (Hospitals, Diagnostic Laboratories, Universities) and Region – Forecast to 2026 report “has been added to offer.

The global immunohistochemistry market is expected to reach $ 3.3 billion by 2026, up from $ 2.3 billion in 2021, at a CAGR of 7.7% during the forecast period 2021 to 2026.

The growth of the market is largely driven by the increase in the geriatric population and the subsequent growth in the prevalence of chronic and infectious diseases, the technological advancements of IHC and the availability of reimbursements for IHC tests. However, the high degree of consolidation of major market players is expected to restrain the growth of this market during the forecast period.

The product kits segment accounted for the highest growth rate of the immunohistochemistry market, by product, during the forecast period.

In 2020, the Kits product segment accounted for approximately 12% of the immunohistochemistry market. The demand for complete solutions from a single source, such as closed system reagents with calibrated measurements of the required amount of reagents and controls among diagnostic laboratories, hospitals, research institutes and other end users, is growing. In addition, the ready-to-use kits simplify the IHC process by rectifying the tedious initial selections of primary antibodies and appropriate stains. This is fueling the growth of the Immunohistochemistry Kits market.

The diagnostic applications segment accounted for the largest share of the applications segment

On the basis of applications, the IHC market is segmented into diagnostic, research, and forensic applications. The diagnostic applications segment dominated this market in 2020 and is expected to register the highest growth during the forecast period. The growth of this segment is mainly attributed to factors such as the advantages of IHC over special enzymatic staining techniques traditionally used which identify only a limited number of proteins, enzymes and tissue structures. Therefore, IHC has become a crucial technique and is widely used for medical research as well as for clinical diagnosis.

Hospitals and diagnostic labs segment accounted for the largest share of the end-user segment

Based on the end user, the IHC market is segmented into diagnostic hospitals and laboratories, academic and research institutes, and other end users. The hospital and diagnostic laboratory segment accounted for the largest share (74.8%) of the IHC market in 2020. The increasing number of specialized diagnostic tests performed in hospital laboratories, the increasing number of diagnostic procedures Internal in hospitals and the increasing trend of establishing internal diagnostic capabilities in hospitals to provide time-bound and affordable patient services are factors driving the growth of this market segment.

Asia-Pacific: Fastest Growing Region in Immunohistochemistry Market

Based on the region, the immunohistochemistry market is broadly segmented to North America, Europe, Asia-Pacific, and the rest of the world. APAC is expected to register the fastest growth rate during the forecast period due to several factors including increasing disposable income, increasing health spending, increasing demand for quality medical care and increased investments by pharmaceutical and biopharmaceutical companies. Growing prevalence of chronic diseases, rapid increase in geriatric population, increasing academic and government investments in diagnostic research, and presence of numerous market players are the other major factors driving the growth of the geriatric market. immunohistochemistry in APAC.

Research coverage

This report provides a detailed picture of the Immunohistochemistry market. It aims to estimate the size and future growth potential of the market in different segments such as product, application, end user and region. The report also includes in-depth competitive analysis of major market players along with their company profile, recent developments and key market strategies.

Lists of profiled companies

  • F. Hoffman-La Roche AG (Switzerland)
  • Danaher Corporation (United States)
  • Agilent Technologies, Inc. (US)
  • Merck KGaA (Germany)
  • Bio-Rad Laboratories, Inc. (United States)
  • Bio-Techne Corporation (United States)
  • Abcam plc (United Kingdom)
  • Becton, Dickinson and Company (United States)
  • PerkinElmer, Inc. (US)
  • Takara Bio, Inc. (Japan)
  • Thermo Fisher Scientific, Inc. (United States)
  • PHC Holdings Corporation (Japan)
  • Cell Signaling Technology, Inc. (US)
  • Bio SB, Inc. (US)
  • Miltenyi Biotec (Germany)
  • CANDOR Bioscience GmbH (Germany)
  • Sakura Finetek Japan Co. Ltd. (Japan)
  • Eagle Biosciences, Inc. (United States)
  • Biocare Medical, LLC (US)
  • Elabscience, Inc. (China)
  • Biogenex Laboratories (United States)
  • Diagnostic Biosystems, Inc. (United States)
  • BioVision Inc. (United States)
  • Rockland Immunochemicals, Inc. (United States)
  • Genemed Biotechnologies, Inc. (United States)

Market dynamics

  • Conductors
    • Increase in the geriatric population and subsequent increase in the prevalence of chronic and infectious diseases
    • Technological advances in IHC
    • Availability of reimbursements for IHC tests
  • Constraints
    • High degree of consolidation
  • Opportunities
    • Growing demand for personalized medicine
    • Growing importance of companion diagnostics
    • Growth opportunities in emerging countries
  • Challenges
    • Shortage of qualified professionals
    • Product failures and recalls

For more information on this report, visit


Source link

Comments are closed.